patients. One patient placed the wafer on top of a rear molar, allowing for the surreptitious removal of the agent a few minutes later. Another method is to place a small piece of tissue or paper towel in the mouth, placing the wafer on top of this barrier. All methods can be easily managed by having the patient swish and swallow water after administering the medication. The characteristics of the wafer make it impossible for "cheeking" to occur, compared with regular pills or capsules.
Leslie Citrome, MD, MPH Orangeburg, New York

Reply: Treatment Noncompliance With Orally Disintegrating Olanzapine Tablets
My letter describing a patient with olanzapine wafer noncompliance had one purpose: to alert clinicians to the possibility of "cheeking" wafers. Dr Citrome describes 2 more "cheeking" techniques and offers an easy remedy. I did not suggest that parenteral drug administration is always (or even usually) the answer to medication nonadherence. I agree with Dr Citrome that persistence with oral atypical antipsychotics (ensuring swishing and swallowing) is preferable to forced parenteral haloperidol, particularly if it leads to a better outcome.
In some cases, however, benefit might never materialize from the patient's perspective, regardless of the medication administered or the route of administration and regardless of clinical response by objective criteria. How prudent and promising is it to insist on repeating daily the drama of drug administration with its checks and obvious coercive element? I would argue that a fail-safe route of infrequent drug administration (for example, with intramuscular haloperidol decanoate) should remain an option to stabilize patients who have little insight into drug benefit. There is no question that these patients present us with complex issues regarding competency, civil rights, and our duties as physicians.
Oliver Freudenreich, MD Boston, Massachusetts
Quetiapine in the Management of Psychosis Secondary to Huntington's Disease: A Case Report
Dear Editor: Psychiatric disorders are common in patients with Huntington's disease (HD) and include mood disorders, anxiety, sexual dysfunction, and psychosis (1) (2) (3) . Although up to 23% of patients with HD have psychotic symptoms (3), the literature regarding management of psychosis secondary to HD is limited to case reports or series. Agents reported to be effective in the management of HD psychosis include clozapine (4), risperidone (5) , and olanzapine (6, 7) . Recent reports indicate that olanzapine (7) and quetiapine (8) may also improve the motor symptoms of HD. However, to our knowledge, no reports exist describing the efficacy of quetiapine in managing psychotic symptoms associated with HD. We describe the first report of quetiapine in the management of psychosis caused by HD.
Mr A, aged 43 years, has a history of HD and psychosis and was admitted to hospital for management of a psychotic episode. Prior to admission, the patient's community treatment team observed that he was not eating, was unable to care for himself, and was experiencing paranoid delusions. He was diagnosed with HD 16 years prior, and his family history was positive for HD. Past treatment of his psychosis included chlorpromazine, haloperidol, lithium, olanzapine, and benzodiazepines. We began treatment with olanzapine, titrating to 20 mg daily.
Olanzapine blood levels were 91 nmol/L at 15 mg daily. Unfortunately, Mr A experienced side effects while taking olanzapine, and his psychosis was poorly controlled. It was decided to discontinue olanzapine, and quetiapine was titrated up to 300 mg daily, while the dosage of olanzapine was tapered over the course of 1 week. We evaluated baseline psychiatric symptomatology, using the Positive and Negative Syndrome Scale (PANSS), on the first day of quetiapine-only therapy and at 8 weeks of quetiapine-only therapy. We evaluated extrapyramidal symptoms (EPS) initially and at 8 weeks, using the Extrapyramidal Symptom Rating Scale (ESRS) (9) .
Initially, the total PANSS score was 68, with subsection scores of 19, 12, and 37 on the positive, negative, and general psychopathology subscales, respectively, at a quetiapine dosage of 300 mg daily. At the start of our study period, the ESRS score was 6. At 8 weeks, the total PANSS score was 53, with subsection scores of 12, 12, and 29 on the positive, negative, and general psychopathology scales, at a quetiapine dosage of 500 mg daily. At 8 weeks, the ESRS score was 12. Serum quetiapine levels at the end of our study were 384 nmol/L. Despite the increase in EPS, Mr A felt subjectively better during quetiapine therapy, compared with olanzapine therapy. Quetiapine appears to be effective in treating the positive symptoms of HD psychosis, with little effect on negative symptomatology. The potential worsening of EPS during quetiapine therapy in HD patients warrants caution in its use, and we suggest careful monitoring for EPS to minimize the impact of these side effects while treating psychotic symptoms. Further large-scale studies are required to evaluate the efficacy of quetiapine in the management of psychosis in HD.
Mrs K, aged 64 years, was admitted to the hospital for markedly elevated blood pressure with subsequent development of nonoliguric renal insufficiency. Upon admission, it was noted that a rash had been present for 2 to 3 weeks. The rash, described as erythematous plaques not involving the nose, was found bilaterally over the cheeks, forearms, scalp, chest, and back. The patient denied other symptoms associated with lupus erythematosus, including polyarthralgia, pleurisy, sun sensitivity, Raynaud's phenomenon, and extremity paresthesias. There was no evidence of connective tissue disease in her past medical history. Her psychiatric history was remarkable for depression with psychosis, for which she received ziprasidone 20 mg daily for approximately 5.5 months.
Rheumatology and dermatology consults were obtained. Both consultants felt that she was likely suffering a reaction to the ziprasidone, rather than a connective tissue disease. Serum autoantibodies, rheumatoid factor, erythrocyte sedimentation rate (sed rate), and punch biopsy were obtained to evaluate the rash. Results of serum tests showed a slightly elevated sed rate at 45 mm/Hr and a positive result for SS-A/Ro autoantibodies at 162.7. Other serum autoantibodies used as markers for druginduced lupus were negative. Results of the punch biopsy were consistent with a drug-induced rash caused by type 3 or 4 hypersensitivity reaction. A literature search on the other medications currently taken by the patient did not reveal an association with drug-induced lupus. Administration of ziprasidone was discontinued, and Mrs K was switched to risperidone at 1 mg daily. She was seen by the consulting dermatologist 4 days after the initial consultation. The dermatologist noted that her rash had improved over the intervening 4 days. Discontinuation of the ziprasidone in conjunction with rapid improvement of signs and symptoms is consistent with the diagnosis of DILE. To our knowledge, this is the first reported case of DILE owing to ziprasidone; thus, it is likely an uncommon phenomenon. Perhaps as our experience with ziprasidone expands, the relevance of DILE as a side effect will be further elucidated.
Lorazepam-Induced Prolongation of the QT Interval in a Patient With Schizoaffective Disorder and Complete AV Block
Dear Editor:A wide range of noncardiovascular therapeutic agents have been shown to prolong the QT interval. The large scope of this problem has created an issue for drug developers and health authorities and is of critical importance for attending physicians (1) . The noncardiac agents associated with QT prolongation belong to many different pharmacologic classes, including psychotropic drugs, prokinetic medicines, antimalarial medicines, antibiotics belonging to several different chemical classes, antifungal agents, and nonsedating antihistamines (2) . In many cases, psychotropic drugs, particularly tricyclic antidepressants and antipsychotic agents, are correlated with iatrogenic prolongation of the QT interval of the ECG (3). This is associated with dangerous polymorphic ventricular tachyarrhythmia torsades de pointes and sudden death. In addition to ventricular conduction time, the QT interval of the ECG reflects the duration of the ventricular action potential (AP) at the cellular level. Thus, the prolongation of the QT interval may reflect effects on ion channels involved in ventricular AP generation. However, the QT interval also depends on the heart rate, and therefore, the determination of QT prolongation in patients is usually measured using the heart-rate corrected QT interval. Vulnerability to medicationinduced prolongation of the QT interval may also reside in the patient, with respect to the underlying psychiatric diagnosis, any underlying medical illness (especially cardiovascular disease), genetic predisposition to drug-induced QT prolongation (4), and patient age. The interactions between different psychotropic drugs used in combination or used with other medications that have known effects on the cardiovascular system may also lead to QT prolongation and risk of arrhythmia.
QT prolongation during lorazepam therapy has not been documented in the literature. We present a case of lorazepam-induced severe QT prolongation.
Case report
A woman, aged 40 years, with an acute schizomanic episode, a third-degree atrioventricular (AV) block, and cardiovascular disease meeting ICD-10 criteria was admitted to our psychiatric hospital. The ECG showed the complete AV block (heart rate 45 bpm, QT interval 394 ms), and the blood tests revealed abnormal findings (elevated creatine kinase and creatine kinase-MB isoenzyme, normal troponin T, and elevated liver enzymes). The electroencephalogram and the brain CT revealed no abnormal findings. Because of the severe symptoms, psychopharmacotherapy with 12.5 mg quetiapine, 100 mg trimipramine, 40 mg pipamperone, and 5 mg diazepam daily was started. The psychopharmacotherapy had no influence on the QT interval. At day 6, 0.5 mg lorazepam was given 3 times, inducing QT prolongation up to 580 ms. Psychopharmacotherapy was discontinued, and the patient was admitted to the medical department for 1 day. The QT prolongation persisted for 7 days, and according to the international treatment criteria, the insertion of a cardiac pacemaker was mandatory. On day 16, a permanent cardiac pacemaker with dualchamber pacing (that is, DDD mode) was implanted. Afterwards, a sophisticated psychopharmacotherapeutic regimen was established, and the patient responded to the therapy.
In this case, we found a constellation of putative risk factors for the development of QT prolongation. We hypothesize that lorazepam induced the QT prolongation. For a given medication, arrhythmogenic risk must be understood to be partially mechanistically dependent on vulnerability intrinsic to the individual patient with regard to the particular drug. We suggest cautious use of psychotropic drugs in patients with risk factors.
